Mr. Federico became a Director of Orthofix International N.V. in October 1996 and was the President of Orthofix Inc. from October 1996 to Jan. 1, 2002. On Jan. 1, 2001, Mr. Federico was appointed President and Chief Executive Officer of Orthofix International N.V. From 1985 to 1996, Mr. Federico was the President of Smith & Nephew Endoscopy (formerly Dyonics, Inc.). From 1981 to 1985, Mr. Federico served as Vice President of Dyonics, initially as Director of Marketing and subsequently as General Manager. Previously, he held management and marketing positions with General Foods Corporation, Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Effective April 1, 2006, Mr. Federico resigned as President and Chief Executive Officer of Orthofix International N.V. but remains on the Board of Directors.

Holdings: 4,325 shares     View Transactions
Date	Type	Shares Traded	Price Range
Dec 5, 2006	Sell	43,800	45.00 - 45.20
Dec 5, 2006	Option Execute	43,800	37.76 - 43.04
Aug 31, 2006	Sell	124,900	39.15 - 39.74
Aug 31, 2006	Option Execute	124,900	17.88 - 37.76
Aug 30, 2006	Sell	125,100	39.76 - 39.90
Aug 30, 2006	Option Execute	125,100	17.88

Mr. Hewett was appointed Deputy Chairman of the Board of Directors in 2005 and has been a non-executive Director of Orthofix International N.V. since March 1992. He was the Deputy Group Chairman of Orthofix International N.V. between March 1998 and December 2000. Previously, Mr. Hewett served as the Managing Director of Caradon Plc, Chairman of the Engineering Division, Chairman and President of Caradon Inc., Caradon Plc's U.S. subsidiary and a member of the Board of Directors of Caradon Plc of England. In addition, he was responsible for Caradon Plc's worldwide human resources function and the development of its acquisition opportunities.

Holdings: 59,800 shares     View Transactions
Date	Type	Shares Traded	Price Range
Nov 5, 2007	Automatic Sell	2,875	52.04 - 52.51
Nov 5, 2007	Option Execute	5,275	10.63
Oct 29, 2007	Automatic Sell	5,750	53.02 - 53.40
Oct 29, 2007	Option Execute	10,550	10.63
Oct 22, 2007	Automatic Sell	5,750	51.45 - 51.70
Oct 22, 2007	Option Execute	10,550	10.63
Oct 15, 2007	Automatic Sell	5,750	50.15 - 50.95
Oct 15, 2007	Option Execute	10,550	10.63
Oct 8, 2007	Automatic Sell	5,750	49.72 - 50.01
Oct 8, 2007	Option Execute	10,550	10.63
Oct 1, 2007	Automatic Sell	2,875	47.91 - 49.45
Oct 1, 2007	Option Execute	5,275	10.63
Sep 24, 2007	Automatic Sell	2,875	46.58 - 47.20
Sep 24, 2007	Option Execute	5,275	10.63
Sep 17, 2007	Automatic Sell	2,875	45.47 - 45.51
Sep 17, 2007	Option Execute	2,875	10.63

Dr. von Wartburg became a non-executive Director of Orthofix International N.V. in June 2004. He is an attorney and has practiced privately in his own law firm in Basel, Switzerland since 1999, specializing in life sciences law. He has also been a professor of administrative law and public health policy at the Saint Gall Graduate School of Economics in Switzerland for 25 years. Previously, he held top management positions with Ciba Pharmaceuticals and Novartis at their headquarters in Basel, Switzerland. In addition, Mr. von Wartburg currently serves as a Director on the board of Nymox Pharmaceutical Corporation.

Dr. Jordan became a non-executive Director of Orthofix International N.V. in December 2004. Most recently, Dr. Jordan served as a group president at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard's global oncology business and functional responsibility for all of Bard's research and development. Dr. Jordan earned a Ph.D. in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University. He also currently serves on the boards of Specialized Health Products International, Inc., Xillix Technologies Corporation and EsophyX, Inc.